Fig. 3: DAPT and sorafenib exhibit therapeutic efficacy in HuKemia^® Acute Myelocytic Xenograft Model AM7577 in Female NOD SCID Mice.

a Schematic diagram of the experimental design. b The tumor burden (percentage of human-CD45-positive leukemia cells versus total live cells) growth curves in PB after grouping. Data represent the average ±SD, n = 12 mice per cohort. c PB engraftment on day 28, represented by the percentage of human CD45⁺ cells. Data represent the average ±SD for cohort vehicle, sorafenib, DAPT, and Combo, n = 6, 5, 4, and 7, respectively. (*P < 0.05, **P < 0.01). d Kaplan–Meier survival of the mouse cohorts (n = 8 each), indicating the median survival of vehicle (28 days), DAPT (29 days), sorafenib (45.5 days), and Combo (52.5 days) group mice (*P < 0.05, ***P < 0.001). e–g Spleen engraftment at the end of treatment, represented by (e) the percentage of hCD45⁺ cells, f organ weight, and g images. Image of the spleen was acquired separately (SONY ILCE-5100), and the original images were trimmed to an equal size of 1.5 cm × 3 cm. Data represent the average of n = 4 mice per cohort ±SD (*P < 0.05, **P < 0.01, ***P < 0.001). h Representative images of organ infiltration (spleen, liver, bone marrow) analyzed by immunohistochemistry (IHC) staining of human CD45 (hCD45). Statistical analysis is shown on the right. Error bars represent the average of three independent experiments ±SD. (*P < 0.05, **P < 0.01, ***P < 0.001). Images were acquired by NIKON Eclipse ci (Tokyo, Japan) at ×400 magnification. Scale bar, 50 μm.